Google
RNXT — RENOVORX INC (Healthcare >> Biotechnology)
RNXT FAQ
What is RNXT's ROE?
RENOVORX INC reports a Return on Equity (ROE) of -108.91%.
What is RNXT's dividend yield?
RENOVORX INC offers a dividend yield of 0.00%.
What is RNXT's Deepscope Quality Score?
Deepscope rates RNXT's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy RNXT?
Deepscope's AI Timing Score for RNXT is 51 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does RNXT belong to?
RENOVORX INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.87
Price
-0.10
(-10.60%)
Day Change
|
|
|---|
RNXT, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 80 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.87 |
| PBV / Sector |
3.92 / 4.63
|
| Earning Per Share | -0.24 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.30 M
GREAT
|
| Average 1W Daily Value |
0.36 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:01 |
| Symbol | RNXT |
| Name | RENOVORX INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 45.10 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 44.19 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2570 West El Camino Real, Mountain View, CA, United States, 94040
Phone: 650 284 4433
Website: https://renovorx.com
Sector: Healthcare >> Biotechnology
Description: RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
